[1]SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
[2]HAN X,CHEN L.Anti-PD-1/PD-L1 therapy of human cancer:past,present,and future［J］.J Clin Invest,2015,125(9):3384-3391.
[3]HUANG MY,JIANG XM,WANG BL,et al.Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer:strategies and mechanisms［J］.Pharmacol Ther,2021,219(1):107694.
[4]OVERMAN MJ,MCDERMOTT R,LEACH JL,et al.Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142):an open-label,multicentre,phase 2 study［J］.Lancet Oncol,2017,18(9):1182-1191.
[5]LE DT,KIM TW,VAN CUTSEM E,et al.Phase II open-label study of pembrolizumab in treatment-refractory,microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer:KEYNOTE-164［J］.J Clin Oncol,2020,38(1):11-19.
[6]MARABELLE A,LE DT,ASCIERTO PA,et al.Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer:results from the phase II KEYNOTE-158 study［J］.J Clin Oncol,2020,38(1):1-10.
[7]JR L,SHIU KK,KIM TW,et al.Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177):final analysis of a randomised,open-label,phase 3 study［J］.Lancet Oncol,2022,23(5):659-670.
[8]石元朝,关泉林.非小细胞肺癌免疫治疗疗效预测的研究进展［J］.现代肿瘤医学,2022,30(02):360-364.
SHI YC,GUAN QL.Progress in the prediction of therapeutic effect of immunotherapy for non-small cell lung cancer［J］.Modern Oncology,2022,30(02):360-364.
[9]LI J,DENG Y,ZHANG W,et al.Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors［J］.J Hematol Oncol,2021,14(1):95.
[10]ZHANG F,WEI H,WANG X,et al.Structural basis of a novel PD-L1 nano-body for immune checkpoint blockade［J］.Cell Discov,2017,3:17004.
[11]MUYLDERMANS S.Single domain camel antibodies:current status［J］.J Biotechnol,2001,74(4):277-302.
[12]IRA M,GEORGE C,GLENN D,et al.Cancer immunotherapy comes of age［J］.Nature,2011,480(7378):480-489.
[13]赵婷婷,张清媛.PD-1/PD-L1介导的肿瘤免疫逃逸在肿瘤微环境中的研究进展［J］.现代肿瘤医学,2021，29(03):520-523.
ZHAO TT,ZHANG QY.Research progress of tumor immune escape mediated by PD-1/PD-L1 in tumor microenvironment［J］.Modern Oncology,2021,29(03):520-523.
[14]BUTTE MJ,KEIR ME,PHAMDUY TB,et al.Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses［J］.Immunity,2007,27(1):111-122.
[15]DANIEL S,BRYAN A,STEPHEN H,et al.Molecular pathways:next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1［J］.Clin Cancer Res,2012,18(24):6580-6587.
[16]PATERSON AM,BROWN KE,KEIR ME,et al.The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo［J］.J Immunol,2011,187(3):1097-1105.
[17]PAPADOPOULOS KP,HARB W,PEER CJ,et al.First-in-human phase I study of envafolimab,a novel subcutaneous single-domain anti-PD-L1 antibody,in patients with advanced solid tumors［J］.Oncologist,2021,26(9):e1514-e1525.
[18]XU JM,QIN S,ZHANG Y,et al.Phase I study of KN035,the first subcutaneously administered,novel fusion anti-PD-L1 antibody in patients with advanced solid tumors in China［J］.J Clin Oncol Conf,2019,37(15):2608.
[19]SHIMIZU T,NAKAJIMA TE,YAMAMOTO N,et al.Phase I study of envafolimab (KN035),a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody,in Japanese patients with advanced solid tumors［J］.Invest New Drugs,2022,40(5):1021-1031.
[20]沈琳,李健,邓艳红,等.恩沃利单抗治疗MSI-H/dMMR晚期实体瘤关键性II期研究数据更新与亚组分析［C］// 2022年CSCO学术年会论文汇编,中国北京,2022.
SHEN L,LI J,DENG YH,et al.Data update and subgroup analysis of critical II phase study of Envafolimab in the treatment of advanced solid tumor in MSI-H/dMMR［C］// Proceedings of the 2022 CSCO Annual Academic Conference,Beijing,China,2022.
[21]刘容锐,殷先利,邓艳红,等.恩沃利单抗联合FOLFOX一线治疗晚期胃/食管胃结合部腺癌的Ⅱ期临床研究［J］.中国新药杂志,2022,31(15):1502-1508.
LIU RR,YIN XL,DENG YH,et al.Phase II clinical study of Envafolimab combined with FOLFOX in the treatment of advanced gastric/esophagogastric junction adenocarcinoma［J］.Chinese Journal of New drugs,2022,31(15):1502-1508.
[22]焦顺昌.恩沃利单抗联合卡铂/顺铂和依托泊苷一线治疗ES-SCLC的Ⅱ期临床研究［C］// 2022年CSCO学术年会论文汇编,中国北京,2022.
JIAO SC.Phase II clinical study of Envafolimab combined with carboplatin/cisplatin and etoposide in the treatment of ES-SCLC［C］// Proceedings of the 2022 CSCO Annual Academic Conference,Beijing,China,2022.
[23]YANG Q,LIU Y,LIU D,et al.Association of polymorphisms in the programmed cell death 1 (PD-1) and PD-1 ligand genes with ankylosing spondylitis in a Chinese population［J］.Clin Exp Rheumatol,2011,29(1):13-18.
[24]BOUSSIOTIS VA.Molecular and biochemical aspects of the PD-1 checkpoint pathway［J］.N Engl J Med,2016,375(18):1767-1778.
[25]XIAO Y,YU S,ZHU B,et al.RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance［J］.J Exp Medi,2014,211(5):943-959.
[26]YU S,LEUNG KM,KIM HY,et al.Blockade of repulsive guidance molecule b (RGMb) inhibits allergen-induced airways disease［J］.J Allergy Clin Immunol,2019,144(1):94-108.
[27]BAXI S,YANG A,GENNARELLI RL,et al.Immune-related adverse events for anti-PD-1 and anti-PD-LI drugs:systematic review and meta-analysis［J］.BMJ,2018,360:k793.
[28]PILLAI RN,BEHERA M,OWONIKOKO TK,et al.Comparison of the toxicity profile of PD-1 versus PD-LI inhibitors in non-small cell lung cancer:A systematic analysis of the literature［J］.Cancer,2018,124(2):271-277.
[29]PEROL M.Multidisciplinary approach of immune checkpoint inhibitor-related pneumonitis:a key to address knowledge and management gaps［J］.J Thorac Oncol,2020,15(8):1261-1264.
[30]KHUNGER M,RAKSHIT S,PASUPULETI V,et al.Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer:a systematic review and meta-analysis of trials［J］.Chest,2017,152(2):271-281.
[31]ANTHONY MARKHAM.Envafolimab:first approval［J］.Drugs,2022,82(2):235-240.